ACOTEC SCIEN.H. DL-00001 (7W3) - Total Liabilities
Based on the latest financial reports, ACOTEC SCIEN.H. DL-00001 (7W3) has total liabilities worth €392.01 Million EUR (≈ $458.30 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
ACOTEC SCIEN.H. DL-00001 - Total Liabilities Trend (2021–2025)
This chart illustrates how ACOTEC SCIEN.H. DL-00001's total liabilities have evolved over time, based on quarterly financial data. See ACOTEC SCIEN.H. DL-00001 working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
ACOTEC SCIEN.H. DL-00001 Competitors by Total Liabilities
The table below lists competitors of ACOTEC SCIEN.H. DL-00001 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kogan.com Ltd
AU:KGN
|
Australia | AU$129.62 Million |
|
Giantplus Technology Co Ltd
TW:8105
|
Taiwan | NT$3.00 Billion |
|
Austindo Nusantara Jaya Tbk
JK:ANJT
|
Indonesia | Rp184.53 Million |
|
Vodafone Group PLC
LSE:VOD
|
UK | GBX75.52 Billion |
|
Rimini Street Inc
NASDAQ:RMNI
|
USA | $380.14 Million |
|
Scpharmaceuticals Inc
NASDAQ:SCPH
|
USA | $101.57 Million |
|
Hubtown Limited
NSE:HUBTOWN
|
India | Rs31.54 Billion |
|
Neuberger Berman IMF Inc
NYSE MKT:NBH
|
USA | $231.69 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down ACOTEC SCIEN.H. DL-00001's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ACOTEC SCIEN.H. DL-00001 (7W3) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.73 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ACOTEC SCIEN.H. DL-00001's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ACOTEC SCIEN.H. DL-00001 (2021–2025)
The table below shows the annual total liabilities of ACOTEC SCIEN.H. DL-00001 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €392.01 Million ≈ $458.30 Million |
+25.34% |
| 2024-12-31 | €312.76 Million ≈ $365.65 Million |
-0.56% |
| 2023-12-31 | €314.53 Million ≈ $367.72 Million |
+133.93% |
| 2022-12-31 | €134.46 Million ≈ $157.19 Million |
+34.23% |
| 2021-12-31 | €100.17 Million ≈ $117.11 Million |
-- |
About ACOTEC SCIEN.H. DL-00001
Acotec Scientific Holdings Limited operates as an interventional medical device company that offers vascular interventional treatment products in Mainland China and internationally. The company's products include AcoArt Orchid & Dhalia, a paclitaxel DCB used to prevent stenosis or occlusion in superficial femoral artery and popliteal artery for the treatment of lower extremity artery disease with… Read more